# Safety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV Infection

> **NCT01909804** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 323 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** SOF
- **DRUG:** VEL
- **DRUG:** RBV

## Key facts

- **NCT ID:** NCT01909804
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2014-05
- **Final completion:** 2014-08
- **Target enrollment:** 323 (ACTUAL)
- **Last updated:** 2018-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01909804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01909804, "Safety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV Infection". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01909804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*